Salix wins OK for ulcerative colitis therapy; Isis bags $18M milestone from GSK;

@FierceBiotech: VC giant NEA recruits a biotech vet to join its ranks of dealmakers. Report | Follow @FierceBiotech

@JohnCFierce: Biotechs tap a swelling tide of investment cash to fund growing R&D ops--or, laissez les bon temps rouler. Story | Follow @JohnCFierce

@DamianFierce: Deal: $AUXL leaves $QLTI at the altar and accepts a $2.6B offer from $ENDP. Release | Follow @DamianFierce

@EmilyMFierce: Ebola genome browser launched to aid drug discovery. FierceBiotech Research story | Follow @EmilyMFierce

> Widely viewed as a likely takeover target, Salix Pharmaceuticals ($SLXP) has nabbed an FDA approval for Uceris, a rectal foam therapy for ulcerative colitis. The therapy is an extended-release version of budesonide. The treatment is a rectally applied corticosteroid. Release

> Carlsbad, CA-based Isis Pharmaceuticals ($ISIS) bagged an $18 million milestone payment from GlaxoSmithKline ($GSK) on the progress for the Phase II/III study of ISIS-TTRRx in patients with familial amyloid polyneuropathy. Release

Medical Device News

@FierceMedDev: Histogenics files for IPO, as Autogenomics refiles again. Article | Follow @FierceMedDev

@VarunSaxena2: HillaryClinton says we have to review +s and -s of device tax. An expected non-answer. | Follow @VarunSaxena2

@EmilyWFierce: Third time's a charm? FDA panel recommends Boston Scientific's Watchman device by a slim margin. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: With $RHHBY's Herceptin, green tea component doubles drug accumulation in #cancer cells. More | Follow @MichaelGFierce

> Boston Scientific wins positive recommendation from FDA panel for stroke-fighting Watchman device. More

> Stealth surgical reconstruction startup Tela-Bio raises $45.4 million. Item

> CoheroHealth to pilot asthma inhaler sensor and app at Mount Sinai Medical Center. Article

Pharma News

@FiercePharma: Top-read in FP Weds: Novartis, GSK shake up executive ranks as overhaul continues. Article | Follow @FiercePharma

@CarlyHFierce: ICYMI, this week's issue of FiercePharmaMarketing is here. And you can subscribe here. | Follow @CarlyHFierce

> Merck can't sidestep $250M gender-bias suit, judge says. Story

> Auxilium dumps QLT inversion deal for $2.6B Endo buyout. Article

Vaccines News

> Pfizer's meningitis B vaccine is effective when given with HPV jab. More

> Sanofi bird flu vax prompts immune response in PhII--but only with Novartis adjuvant. Story

> Biotechs angling for T-cell response in race for next-gen herpes vaccine. Article

> Takeda appoints new vax development head as Novartis' Oswald heads for the door. Report

> Could 'space bacteria' help create vaccines? Item

Pharma Manufacturing News

> Impax says $700M deal for Tower will help it deal with quality issues. More

> Hospira recalls drug because of storage glitch during shipping. Report

> France's Ceva has completed a sterile facility for vet drugs. Item

> Gerresheimer adjusts earnings forecast lower in wake of FDA crackdown. Article

> CSL announces $450M commitment to expand two of its plants. Story

Suggested Articles

Combining inhibitors of KRAS-G12C, mTOR and IGF1R can significantly shrink lung tumors in mice and human cancer cells, a study found.

X4 Pharmaceuticals has a new R&D chief: Renato Skerlj, who founded the company alongside CEO Paula Ragan and biotech luminary Henri Termeer.

Henlius Biotech missed the $477 million goal it set for its IPO, but still made the top five biopharma IPOs this year with its $410 million listing.